Tags : P-III

Biosimilars

Tanvex Reports Results of TX05 (biosimilar, trastuzumab) in P-III Study

Shots: The P-III study evaluates the efficacy and safety of TX05 vs Herceptin (trastuzumab) in patients with human epidermal growth factor receptor 2-positive early breast cancer The 1EPs was an assessment of pCR following neoadjuvant therapy and definitive surgery in the per-protocol population Results: Patients achieved pCR (48.8% vs 45.3%) in the per-protocol population Click […]Read More